IMMUNE CELL ENGINEERING MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Immune cell engineering is a field that has gained significant attention in recent years due to its potential to revolutionize the treatment of various diseases, including cancer. It involves the manipulation and modification of immune cells to enhance their ability to target and destroy cancer cells or other pathogens. This emerging field combines principles of immunology, molecular biology, and genetic engineering to develop innovative therapies.

The immune system plays a critical role in recognizing and eliminating foreign invaders or abnormal cells in the body. However, in some cases, the immune response may be insufficient or ineffective against certain diseases. By genetically modifying immune cells, scientists can enhance their ability to recognize and attack specific targets, such as cancer cells.

Market Dynamics:

The immune cell engineering market is driven by several key factors. Firstly, there is a growing prevalence of various diseases, including cancer, autoimmune disorders, and infectious diseases. As traditional treatment options for these diseases often have limitations, there is a need for innovative therapeutic approaches.

Secondly, advancements in gene-editing technologies have significantly improved the efficiency and precision of immune cell engineering. Gene-editing tools such as CRISPR/Cas9 have made it easier to modify immune cells and enhance their therapeutic potential. These technological innovations are expected to drive the growth of the immune cell engineering market.

However, there are also several challenges and restraints that need to be addressed. One of the main challenges is the high cost associated with immune cell engineering therapies. The development and manufacturing processes for these therapies are complex and require specialized facilities and expertise. This has limited the accessibility of these therapies, particularly in developing countries.

For instance, in December 2022, Gilead Sciences, Inc., a pharmaceutical company, announced the acquisition of Tmunity Therapeutics Inc., a clinical-stage biotechnology company. The acquisition provided Gilead Sciences, Inc. with preclinical and clinical programs, including an “armored” CAR T technology platform that has the potential to be applied to a variety of CAR T cells to enhance anti-tumor activity, and helps to enhance manufacturing processes for of CAR T cells product.

Key features of the study:

• This report provides in-depth analysis of the global immune cell engineering market, and provides market size (US$ Bn) and compound annual growth rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global immune cell engineering market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Thermo Fisher Scientific Inc., Merck KGaA, Danaher Corporation, Lonza, Miltenyi Biotec, Takara Bio Inc., Sartoroius CellGenix GmbH, FUJIFILM Irvine Scientific, Agilent Technologies, Inc., Bio-Techne, Bio-Rad Laboratories, Inc., Becton, Dickinson and Company, Charles River Laboratories, Creative Bioarray, Sartorius AG, Novogene Co, Ltd., AGC Biologics, Catalent, Inc., WuXi AppTec, Discovery Life Sciences
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global immune cell engineering market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global immune cell engineering market

Detailed Segmentation:

• Global Immune Cell Engineering Market, By Cell Type
• • T Cells
  • NK Cells
  • Dendritic Cells
  • Tumor Cells
  • Stem Cells
  • Others
• Global Immune Cell Engineering Market, By Product
• • Consumables
  • Instruments
  • Software
• Global Immune Cell Engineering Market, By Disease Indication
• • Cardiovascular Diseases
  • Respiratory Diseases
  • Infectious Diseases
  • Cancer
  • Neurological Diseases
  • Others
• Global Immune Cell Engineering Market, By Application
• • Research Applications
  • Cell Therapy & Regenerative Medicine
  • Others
• Global Immune Cell Engineering Market, By End User
• • Pharmaceutical & Biotechnology Companies
  • Hospitals & Clinics
  • Academic & Research Institutes
  • Cell Banks
  • Others
• Global Immune Cell Engineering Market, By Region
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
• Top companies in Immune Cell Engineering Market:
• • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Lonza
  • Miltenyi Biotec
  • Takara Bio Inc.
  • Sartoroius CellGenix GmbH
  • FUJIFILM Irvine Scientific
  • Agilent Technologies, Inc.
  • Bio-Techne
  • Bio-Rad Laboratories, Inc.
  • Becton, Dickinson and Company
  • Charles River Laboratories
  • Creative Bioarray
  • Sartorius AG
  • Novogene Co, Ltd.
  • AGC Biologics
  • Catalent, Inc
  • WuXi AppTec
  • Discovery Life Sciences